Biopharmaceutical aspects of ritodrine retard in pregnant women. 1988

G G Essed, and H A Struyker Boudier, and J A Van Zijl
Department of Obstetrics and Gynaecology, Academic Hospital, State University of Limburg, Maastricht, The Netherlands.

Biopharmaceutical aspects of the new sustained-release formulation of ritodrine, a tocolytic agent, were studied in 9 patients with preterm labour. A mean bioavailability of 26% (range 22%-32%) was estimated after the 4th day of treatment (steady state). A.U.C.'s from oral administration were found to correlate well with those measured in i.v. therapy in the same patients (r = 0.92; p = 0.0004). It was concluded that differences in bioavailability of ritodrine-retard are small enough to enable clinicians, using this sustained release preparation, to make fair estimations of the oral dosage, needed to replace the initial i.v. treatment.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007752 Obstetric Labor, Premature Onset of OBSTETRIC LABOR before term (TERM BIRTH) but usually after the FETUS has become viable. In humans, it occurs sometime during the 29th through 38th week of PREGNANCY. TOCOLYSIS inhibits premature labor and can prevent the BIRTH of premature infants (INFANT, PREMATURE). Preterm Labor,Labor, Premature,Premature Labor,Premature Obstetric Labor,Labor, Premature Obstetric,Labor, Preterm
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D005865 Gestational Age The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated from the onset of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization. It is also estimated to begin from fertilization, estrus, coitus, or artificial insemination. Embryologic Age,Fetal Maturity, Chronologic,Chronologic Fetal Maturity,Fetal Age,Maturity, Chronologic Fetal,Age, Embryologic,Age, Fetal,Age, Gestational,Ages, Embryologic,Ages, Fetal,Ages, Gestational,Embryologic Ages,Fetal Ages,Gestational Ages
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001702 Biopharmaceutics The study of the physical and chemical properties of a drug and its dosage form as related to the onset, duration, and intensity of its action. Pharmaceutics,Pharmaceutic

Related Publications

G G Essed, and H A Struyker Boudier, and J A Van Zijl
December 1983, American journal of obstetrics and gynecology,
G G Essed, and H A Struyker Boudier, and J A Van Zijl
December 2010, International journal of dermatology,
G G Essed, and H A Struyker Boudier, and J A Van Zijl
October 1987, European journal of obstetrics, gynecology, and reproductive biology,
G G Essed, and H A Struyker Boudier, and J A Van Zijl
June 1992, BMJ (Clinical research ed.),
G G Essed, and H A Struyker Boudier, and J A Van Zijl
January 1997, Journal of the American College of Surgeons,
G G Essed, and H A Struyker Boudier, and J A Van Zijl
May 1990, American journal of obstetrics and gynecology,
G G Essed, and H A Struyker Boudier, and J A Van Zijl
April 1977, British medical journal,
G G Essed, and H A Struyker Boudier, and J A Van Zijl
September 1977, British medical journal,
G G Essed, and H A Struyker Boudier, and J A Van Zijl
July 1977, British medical journal,
G G Essed, and H A Struyker Boudier, and J A Van Zijl
March 1983, Obstetrics and gynecology,
Copied contents to your clipboard!